Abiopharma

Kymera Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025

IQVIA Reports Third-Quarter 2025 Results

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Natera Reports Strong Advanced Adenoma Data from Prospective PROCEED-CRC Trial, Demonstrating 22.5% Sensitivity and 91.5% Specificity

Merck Announces KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Clear Cell Renal Cell Carcinoma (RCC) Following Nephrectomy

Tenet Reports Strong Third Quarter 2025 Results; Raises 2025 Financial Outlook

RNA Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Avidity Biosciences, Inc. Is Fair to Shareholders

Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025

Regeneron Reports Third Quarter 2025 Financial and Operating Results

GeneDx Reports Third Quarter 2025 Financial Results and Business Highlights